Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for

[News]

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

More... (http://www.news-medical.net/news/20110921/Enrollment-commences-in-Boehringer-Ingelheims-TOviTO-Phase-III-combination-trial-for-COPD.aspx)